C07C13/04

Process for the preparation of (3E, 7E)-homofarnesol

The present invention relates to new types of processes for the improved preparation of homofarnesol, in particular of (3E,7E)-homofarnesol and homofarnesol preparations with an increased content of (3E,7E)-homofarnesol (also referred to as all E-homofarnesol).

Process for the preparation of (3E, 7E)-homofarnesol

The present invention relates to new types of processes for the improved preparation of homofarnesol, in particular of (3E,7E)-homofarnesol and homofarnesol preparations with an increased content of (3E,7E)-homofarnesol (also referred to as all E-homofarnesol).

Pyruvate kinase activators for use in therapy
09682080 · 2017-06-20 · ·

Described herein are methods for using compounds that activate pyruvate kinase.

Cyclopropanation

A method of preparing a cyclopropane ring-bearing compound of the formula I ##STR00001##
in which R.sup.1 and R.sup.2 are independently selected from C.sub.1-C.sub.10 alkyl, optionally substituted, or R.sup.1 and R.sup.2, together with the bonds linking them to the cyclopropane ring, form a monocyclic or bicyclic ring system, which may comprise at least one hetero-atom, comprising the reaction of a compound of formula II
R.sup.1CHCHR.sup.2II
in which R.sup.1 and R.sup.2 have the significances hereinabove defined, with a compound of formula III
XCH.sub.2YIII
in which X is a nucleofuge selected from halides and pseudohalides and Y is an electrofuge selected from boranes and borates, in the presence of a metal catalyst complex selected from those useful for catalytic cyclopropanation and those useful for catalyzing Heck coupling. The method provides a particularly easy and non-hazardous method of cyclopropanation.

Cyclopropanation

A method of preparing a cyclopropane ring-bearing compound of the formula I ##STR00001##
in which R.sup.1 and R.sup.2 are independently selected from C.sub.1-C.sub.10 alkyl, optionally substituted, or R.sup.1 and R.sup.2, together with the bonds linking them to the cyclopropane ring, form a monocyclic or bicyclic ring system, which may comprise at least one hetero-atom, comprising the reaction of a compound of formula II
R.sup.1CHCHR.sup.2II
in which R.sup.1 and R.sup.2 have the significances hereinabove defined, with a compound of formula III
XCH.sub.2YIII
in which X is a nucleofuge selected from halides and pseudohalides and Y is an electrofuge selected from boranes and borates, in the presence of a metal catalyst complex selected from those useful for catalytic cyclopropanation and those useful for catalyzing Heck coupling. The method provides a particularly easy and non-hazardous method of cyclopropanation.

PROCESS FOR THE PREPARATION OF (3E, 7E)-HOMOFARNESOL

The present invention relates to new types of processes for the improved preparation of homofarnesol, in particular of (3E,7E)-homofarnesol and homofarnesol preparations with an increased content of (3E,7E)-homofarnesol (also referred to as all E-homofarnesol).

PROCESS FOR THE PREPARATION OF (3E, 7E)-HOMOFARNESOL

The present invention relates to new types of processes for the improved preparation of homofarnesol, in particular of (3E,7E)-homofarnesol and homofarnesol preparations with an increased content of (3E,7E)-homofarnesol (also referred to as all E-homofarnesol).

PROCESS FOR THE PREPARATION OF (3E, 7E)-HOMOFARNESOL

The present invention relates to new types of processes for the improved preparation of homofarnesol, in particular of (3E,7E)-homofarnesol and homofarnesol preparations with an increased content of (3E,7E)-homofarnesol (also referred to as all E-homofarnesol).

Pyruvate kinase activators for use in therapy

Described herein are methods for using compounds that activate pyruvate kinase.

PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY
20250332161 · 2025-10-30 ·

Described herein are methods for using compounds that activate pyruvate kinase.